WEKO3
アイテム
{"_buckets": {"deposit": "f62f53bd-2e45-473c-9f88-2f7d4d8cfe79"}, "_deposit": {"created_by": 1, "id": "80200", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "80200"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00080200", "sets": ["28"]}, "author_link": ["878005", "878004", "878003", "878002", "878010", "878006", "878009", "878015", "878007", "878011", "878014", "878013", "878012", "878008", "878001", "878000"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2020-07-12", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: Noninvasive positron emission tomography (PET) imaging of vascular endothelial growth factor receptor 2 (VEGFR-2) expression could be a valuable tool for evaluation of patients with a variety of malignancies, and particularly for monitoring those undergoing antiangiogenic therapies that block VEGF/VEGFR-2 function. VEGF125-136 (QKRKRKKSRYKS) is a 12 amino acid peptide encoded by exon 6 of VEGF-A which was first identified as an effective inhibitor to VEGFR-2. The aim of this work was to develop and evaluate in mice the 64Cu labelled analogue as an in vivo tracer for VEGFR-2 expression in solid tumours.\n\nMethods: VEGF125-136 was conjugated with PEG3 and DOTA and then labeled with 64Cu (denoted as [64Cu]VEGF125-136) for small-animal PET of mice bearing B16F10 human melanoma cells, U87MG human glioblastoma cells, and MDA-231 human breast cancer xenografts. Biodistribution studies, autoradiography and immunofluorescence staining were carried out to confirm the noninvasive imaging results.\n\nResults: The radiolabeling yield and specific activity of [64Cu]VEGF125-136 were more than 95% and 74.3 ± 3.8 GBq/µmol, respectively. Noninvasive microPET showed that [64Cu]VEGF125-136 had variable uptake in different tumors, with the order: B16F10 \u003e U87MG \u003e MDA-231. The pattern of radiotracer uptake was correlated well with variations in VEGFR-2 expression determined ex vivo by immunohistochemical analysis. Moreover, the tracer showed high tumor uptake (5.89 ± 2.58 %ID/g at 20 min postinjection in B16F10 mice) and excellent pharmacokinetics, achieving the maximum imaging quality within 1 h after injection. Biodistribution studies and autoradiography confirmed the VEGFR-2 specificity of [64Cu]VEGF125-136.\n\nConclusions: We have developed a VEGFR-2-specific PET tracer, [64Cu]VEGF125-136. This tracer may be translated into the clinic for imaging tumor angiogenesis and monitoring antiangiogenic treatment efficacy.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "SNMMI 2020 Annual Meeting", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kuan, Hu"}], "nameIdentifiers": [{"nameIdentifier": "878000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shang, Jingjie"}], "nameIdentifiers": [{"nameIdentifier": "878001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Xie, Lin"}], "nameIdentifiers": [{"nameIdentifier": "878002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hanyu, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "878003", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding"}], "nameIdentifiers": [{"nameIdentifier": "878004", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yang, Zhimin"}], "nameIdentifiers": [{"nameIdentifier": "878005", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Xu, Hao"}], "nameIdentifiers": [{"nameIdentifier": "878006", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Lu, Wang"}], "nameIdentifiers": [{"nameIdentifier": "878007", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ming-Rong, Zhang"}], "nameIdentifiers": [{"nameIdentifier": "878008", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878009", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Xie, Lin", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878010", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hanyu, Masayuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878011", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878012", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yang, Zhimin", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878013", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Lu, Wang", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878014", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ming-Rong, Zhang", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "878015", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with a new 64Cu labeled peptide", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with a new 64Cu labeled peptide"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/80200", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-07-06"}, "publish_date": "2020-07-06", "publish_status": "0", "recid": "80200", "relation": {}, "relation_version_is_last": true, "title": ["Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with a new 64Cu labeled peptide"], "weko_shared_id": -1}
Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with a new 64Cu labeled peptide
https://repo.qst.go.jp/records/80200
https://repo.qst.go.jp/records/80200c30bbecf-5f81-44e6-bf0d-46c98955a761
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-07-06 | |||||
タイトル | ||||||
タイトル | Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with a new 64Cu labeled peptide | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kuan, Hu
× Kuan, Hu× Shang, Jingjie× Xie, Lin× Hanyu, Masayuki× Zhang, Yiding× Yang, Zhimin× Xu, Hao× Lu, Wang× Ming-Rong, Zhang× Kuan, Hu× Xie, Lin× Hanyu, Masayuki× Zhang, Yiding× Yang, Zhimin× Lu, Wang× Ming-Rong, Zhang |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: Noninvasive positron emission tomography (PET) imaging of vascular endothelial growth factor receptor 2 (VEGFR-2) expression could be a valuable tool for evaluation of patients with a variety of malignancies, and particularly for monitoring those undergoing antiangiogenic therapies that block VEGF/VEGFR-2 function. VEGF125-136 (QKRKRKKSRYKS) is a 12 amino acid peptide encoded by exon 6 of VEGF-A which was first identified as an effective inhibitor to VEGFR-2. The aim of this work was to develop and evaluate in mice the 64Cu labelled analogue as an in vivo tracer for VEGFR-2 expression in solid tumours. Methods: VEGF125-136 was conjugated with PEG3 and DOTA and then labeled with 64Cu (denoted as [64Cu]VEGF125-136) for small-animal PET of mice bearing B16F10 human melanoma cells, U87MG human glioblastoma cells, and MDA-231 human breast cancer xenografts. Biodistribution studies, autoradiography and immunofluorescence staining were carried out to confirm the noninvasive imaging results. Results: The radiolabeling yield and specific activity of [64Cu]VEGF125-136 were more than 95% and 74.3 ± 3.8 GBq/µmol, respectively. Noninvasive microPET showed that [64Cu]VEGF125-136 had variable uptake in different tumors, with the order: B16F10 > U87MG > MDA-231. The pattern of radiotracer uptake was correlated well with variations in VEGFR-2 expression determined ex vivo by immunohistochemical analysis. Moreover, the tracer showed high tumor uptake (5.89 ± 2.58 %ID/g at 20 min postinjection in B16F10 mice) and excellent pharmacokinetics, achieving the maximum imaging quality within 1 h after injection. Biodistribution studies and autoradiography confirmed the VEGFR-2 specificity of [64Cu]VEGF125-136. Conclusions: We have developed a VEGFR-2-specific PET tracer, [64Cu]VEGF125-136. This tracer may be translated into the clinic for imaging tumor angiogenesis and monitoring antiangiogenic treatment efficacy. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | SNMMI 2020 Annual Meeting | |||||
発表年月日 | ||||||
日付 | 2020-07-12 | |||||
日付タイプ | Issued |